Thrombin Inhibitor

FXIIa-IN-1-IN-2 (Compound 21) is a Factor XIIa inhibitor (K_i^app: 62.2 nM). FXIIa-IN-1-IN-2 can be used for research of thrombosis.

Propacetamol (hydrochloride) (Standard) is the analytical standard of Propacetamol (hydrochloride). This product is intended for research and analytical applications. Propacetamol hydrochloride is a potent, peptidic inhibitor targeting thrombin and granzyme GZMK. Propacetamol hydrochloride specifically blocks the activities of thrombin and GZMK, thereby inhibiting thrombin-mediated PAR-1 cleavage, as well as downstream inflammatory and procoagulant signaling pathways. Through stabilizing IκB proteins, blocking NF-κB activation and reducing systemic levels of proinflammatory/procoagulant biomarkers, Propacetamol hydrochloride exerts multiple effects including anti-inflammatory, antithrombotic, barrier repair, and inhibition of atherosclerotic plaque progression. Propacetamol hydrochloride binds to platelets without interference from kininogen, effectively limiting acute thrombus growth and reducing eosinophil infiltration and goblet cell hyperplasia in asthma models. Propacetamol hydrochloride is an important tool molecule for investigating the mechanisms of atherosclerosis, asthma and related thromboinflammatory diseases.

Pirmagrel is a thrombin synthetase inhibitor. Pirmagrel has inhibitory effects on thrombin secretion stimulated by lipopolysaccharide (HY-D1056).

LB30057 (CI-1028) is an orally active selective thrombin inhibitor with an IC₅₀ value of 0.38 nM for human thrombin. LB30057 can be used in the study of the thrombus model.

Thrombin inhibitor 1 is a potent thrombin inhibitor (K_i=0.66 nM, 2xaPTT=0.43 μM).